ZEALAND PHARMA/S (NASDAQ:ZEAL) had its price objective upped by Morgan Stanley from $29.00 to $30.00 in a research note published on Monday, BenzingaRatingsTable reports. They currently have an overweight rating on the stock.
Several other equities research analysts have also commented on ZEAL. Needham & Company LLC reissued a buy rating and set a $32.00 price objective (up previously from $29.00) on shares of ZEALAND PHARMA/S in a research note on Thursday, August 15th. Zacks Investment Research lowered shares of ZEALAND PHARMA/S from a buy rating to a hold rating in a research note on Saturday, July 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $27.33.
NASDAQ:ZEAL opened at $21.24 on Monday. ZEALAND PHARMA/S has a one year low of $11.51 and a one year high of $23.55. The company’s 50-day simple moving average is $22.11 and its 200 day simple moving average is $19.29. The firm has a market capitalization of $651.06 million, a P/E ratio of 7.08 and a beta of 1.91.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $7.50 million. As a group, analysts anticipate that ZEALAND PHARMA/S will post -2.1 earnings per share for the current year.
An institutional investor recently bought a new position in ZEALAND PHARMA/S stock. Susquehanna International Group LLP acquired a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,348 shares of the company’s stock, valued at approximately $331,000. 9.08% of the stock is owned by institutional investors and hedge funds.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
See Also: What are catch-up contributions?
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.